Buradasınız

Anasayfa » Content

Türk Erişkinlerinde Hafif Böbrek Fonksiyon Bozukluğu: Yaygınlığı ve İnsülin Direnci ile Yakın İlişkisi

Mild Renal Dysfunction Among Turkish Adults: Prevalence and Its Association With Insulin Resistance

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives: To investigate the prevalence of mild renal dysfunction and its association with insulin resistance (IR), meta¬bolic syndrome (MS) or its components among Turkish adults. Methods: Serum creatinine concentrations were measured in 1048 male and female subjects. After excluding cases with diabetes mellitus, 933 participants of a representative cohort were studi¬ed cross-sectionally. Glomerular filtration rate (GFR) was estimated based on serum creatinine concentrations using the Modification of Diet in Renal Disease formula. GFR was divided into 3 categori¬es constituting chronic kidney disease stages 2 and >3. MS was identified by modified criteria of the Adult Treatment Panel-III. Results: MS existed in 38.7% of the cohort. Mild renal dysfunction (estimated GFR 60 to 89.9 mL/min/1.73 m2) existed in 50% of the study sample in both genders. Compared to the group with normal GFR, in category II, age-adjusted estimates of body mass index, homeostatic model assessment (HOMA) index, blood pres¬sures, total, HDL-, LDL-cholesterol and serum proteins were all sig¬nificantly elevated in both genders, as were apo B and log TSH in women alone. Stated variables were also significantly and inver¬sely correlated with GFR. Whereas MS was not significantly asso¬ciated with GFR categories, nor with reduced GFR when controlled for HOMA, HOMA -adjusted for MS as well as for sex, age and systolic BP- was significantly associated with likelihood for redu¬ced GFR.Conclusions: Mild impairment of kidney function is very com¬mon in nondiabetic middle-aged and elderly adults, is associated mainly with IR and related cardiovascular risk factors, in the absen¬ce of MS-related atherogenic dyslipidemia. IR is important even in mild reduction in GFR, an action independent of central obesity-re¬lated components of MS.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Halkımızda serum kreatininde hafif bozukluğun ve bunun yansıttığı böbrek fonksiyon bozukluğunun yaygınlığı ve bunun insülin direnci (IR), metabolik sendrom (MS) veya bileşenleri ile arasındaki ilişkinin araştırılması. Yöntem: Serum kreatinin konsantrasyonları 1048 erkek ve kadında ölçüldü. Diyabet hastaları dışlandıktan sonra geri kalan 933 kişide glomerüler filtrasyon hızı da (GFR) Renal Hastalıkta Diyet Modifikasyonu förmülü esas alınarak kreatinin değerlerine göre tahmin edildi. GFR değerlerine göre bireyler evre 2 ve evre >3 kro¬nik böbrek hastalığı olanları da içerecek şekilde üç kategoriye ayrıldı. MS tanımı modifiye Adult Treatment Panel-III (ATP-III) kriterlerine göre yapıldı. Bulgular: Kohortun %38.7'inde MS mevcuttu. Hafif renal fonksiyon bozukluğu (MRD) varlığı (tahmini GFR: 60-89.9 mL/dak/1.73 m2 olanlar) her iki cinsiyet için geçerli olmak üzere çalışma popülasyonu-nun %50'sinde saptandı. Normal GFR'li grupla karşılaştırıldığında grup II'de, yaşa göre ayarlanmış vücut kitle indeksi (VKİ), homeostatik model değerlendirme (HOMA) indeksi, kan basınçları, total, HDL-kolesterol, LDL-kolesterol ve serum proteinleri her iki cinsiyet için, apo B ve log TSH değerleri ise yalnız kadınlarda anlamlı olarak yüksekti. Üstelik belirtilen değişkenler ile GFR arasında anlamlı ve ters bir ilişki de mevcuttu. Çokdeğişkenli analizde MS varlığı ile ne GFR grupları arasında, ne de HOMA için kontrollü azalmış GFR olasılığı arasında anlamlı bir ilişki vardı. Oysa cinsiyet, yaş ve sistolik kan basıncı yanısıra MS için ayarlı HOMA değerleri ile azalmış GFR olasılığı arasında anlamlı bir ilişki bulundu. Sonuç: Diyabeti bulunmayan orta ve ileri yaştaki erişkinlerimizin yarısında böbrek fonksiyonlarında hafif bozukluk mevcut olup bu, MS ile ilişkili aterojen dislipidemi bulunmaksızın, esas itibariyle IR ile ilişkilidir. IR varlığı, MS'in santral obezite ile ilişkili öğelerinden bağımsız biçimde, GFR'deki hafif azalmada bile önemli rol oynar.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_15_pp_197-206.pdf
  • 4
197-206
  • Turkish

REFERENCES

References: 

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
2. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kid¬ney function stage in the US general population: the NHANES III study.
Mayo Clin Proc 2005;80:1270-7.
3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000;35(suppl 1):S117-S131.
4. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk fac¬tors in chronic renal insufficiency. Clin Nephrol 2002;57;327-35
5. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Car¬diovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
6. Shlipak MG, Fried LF, Crump C, et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 2002;62:997-1004.
7. Weiner DE, Tighiouart H, Amin MG, et al: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;16:1307-15.
8. Chen J, Muntner P, Hamm LL, et al:. The metabolic syndrome and chro¬nic kidney disease in U.S. adults. Ann Intern Med 2004;140:167-74
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification: Kid¬ney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39(suppl
2):S1-S246.
10. Rigalleau V, Lasseur C, Perlemoine C, et al: Estimation of glomerular filt¬ration rate in diabetic subjects. Cockcroft formula or Modification of Di¬et in Renal Disease study equation? Diabetes Care 2005;28:838-43.
11. Kubo M, Kiyohara Y, Kato I, et al: Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. Kidney
Int 1999;55:2450-56.
12. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, He J. Insulin resistance and risk of chronic kidney disease in nondiabetic US
adults. J Am Soc Nephrol 2003;14:469-77.
13. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PWF, Levy D. Glycemic
status and development of kidney disease. Diabetes Care 2005;28:2436-
40.
14. Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V: Metabolic syndrome: major impact on coronary risk in a population with low cho¬lesterol levels - a prospective and cross-sectional evaluation. Atherosc¬lerosis 2002;165:285-92.
15. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclero¬sis 2001;156:1-10.
16. Onat A, Avcı Gfi, fienocak M, Örnek E, Gözükara Y. Plasma lipids and their interrelation in Turkish adults. J Epidem Commun Health
1992;46:470-476.
17. Genuth S, Alberti KG, Bennett P, et al: Expert Committee on the Diag¬nosis and Classification of Diabetes Mellitus. Follow-up report on the di¬agnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:3160-7.
18. Executive Summary of the Third Report of the National Cholesterol Edu¬cation Program (NCEP) Expert Panel on detection, evaluation and treat¬ment of high blood cholesterol in adults (Adult Treatment Panel III). JA¬MA 2001;285:2486-2497.
19. Onat A, Hergenç G, Türkmen S, Yazıcı M, Sarı İ, Can G. Discordance between Insulin resistance and metabolic syndrome: features and asso¬ciated cardiovascular risk in adults with normal glucose regulation. Me¬tabolism 2006;55:445-52.
20. Onat A, Hergenç G, Uzunlar B, et al: Determinants of HDL-cholesterol and its prediction of coronary disease among Turks (Summary in Eng¬lish). Arch Turk Soc Cardiol 2003;31:9-16.
21. Wyszynski DF, Waterworth DM, Barter PJ, et al: Relation between athe-rogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Pro¬ject). Am J Cardiol 2005;95:194-198.
22. Mather KJ, Hunt AE, Steinber HO, et al: Repeatability characteristics of simple indices of insulin resistance: implications for research applicati¬ons. J Clin Endocrinol Metab 2001;86:5457-64.
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more ac¬curate method to estimate glomerular filtration rate from serum creatini-ne: a new prediction equation. Modification of Diet in Renal Disease
Study Group. Ann Intern Med 1999;130:461-70.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentrati¬on of low-density-lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
25. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk
of developing renal dysfunction: the Atherosclerosis Risk in Communiti¬es study. Kidney Int 2000;58:293-301.
26. Segura JN, Campo C, Roldan C, Christiansen H, Vigil L, Garcia-Robles R,
Rodicio JL, Ruilope LM. Hypertensive renal damage in metabolic syndro¬me is associated with glucose metabolism disturbances. J Am Soc Neph-
rol 2004;15:S37-S42.
27. Fliser D, Pacini G, Engelleiter R, et al:. Insulin resistance and hyperinsuli-
nemia are already present in patients with incipient renal disease. Kid¬ney Int 1998;53:1343-7.
28. Eidemak I, Feldt-Rasmussen B, Kanstrup IL, Nielsen SL, Schmitz O, Strandgaard S. Insulin resistance and hyperinsulinemia in mild to mode¬rate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 1995;38:565-72.
29. Shlipak MG, Fried LF, Crump C, et al. Elevations in inflammatory and pro-
coagulant biomarkers in elderly persons with renal insufficiency. Circu¬lation 2003;107:87-92.
30. Stuweling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, de Zeeuw
D. C-reactive protein is associated with renal function abnormalities in a nondiabetic population. Kidney Int 2003;63:654-61.

Thank you for copying data from http://www.arastirmax.com